AOD-9604 vs FOXO4-DRI
Compare the research profiles of AOD-9604 and FOXO4-DRI. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesAOD-9604
AOD-9604 (Anti-Obesity Drug)
weight-loss
Phase 2 Clinical Trials (discontinued)
not-approved
FOXO4-DRI
FOXO4-D-Retro-Inverso
senolytic
Preclinical
not-approved
Detailed Comparison
| Aspect | AOD-9604 | FOXO4-DRI |
|---|---|---|
| Overview | A fragment of human growth hormone (amino acids 177-191) marketed specifically for fat burning without affecting blood sugar or causing GH-related side effects. Now banned from compounding by FDA.... | A promising senolytic peptide being researched for its potential to clear senescent ("zombie") cells to reverse aspects of biological aging. Showed dramatic results in aged mice.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Mimics the fat-burning effects of growth hormone without affecting blood sugar or cell proliferation. Stimulates lipolysis (fat breakdown) and inhibit... | Disrupts the interaction between FOXO4 and p53 in senescent cells, triggering apoptosis (cell death) specifically in these damaged cells while leaving... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.